Edico GenomeUnited States of America
Acquired By: Illumina Inc.
Edico Genome has created an end-to-end platform solution for analysis of next-generation sequencing data, DRAGENÂ™, which speeds whole genome data analysis from hours to minutes while maintaining high accuracy and reducing costs. Top clinicians and researchers are utilizing the platform to achieve faster diagnoses for critically ill newborns, cancer patients and expecting parents waiting on prenatal tests, and faster results for scientists and drug developers.
United States of America
- (15.May.2018) Illumina Acquires Edico Genome to Accelerate Genomic Data Analysis
- (13.Mar.2018) Edico Genome Announces Flagship Global Distribution Partnership Program
- (27.Feb.2018) Victorian Clinical Genetics Services and Edico Genome Deploy First DRAGEN Bio-IT Platform in Australia
- (26.Feb.2018) Edico Genome and InterSystems Partner to Streamline Clinical Next-Generation Sequencing Workflows